 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that second quarter of fiscal year 2024 financial...

Surmodics to Report Second Quarter of Fiscal 2024 Financial Results on May 1

This is a Bullish indicator signaling SRDX's price could rise from here. Traders may explore going long the stock or buying call options...

Surmodics (SRDX, $28.9) Moving Average Convergence Divergence (MACD) Histogram turned positive on March 27, 2024

This is a signal that SRDX's price could be shifting from a downtrend to an uptrend. Traders may consider buying the stock or exploring call options...

Surmodics (SRDX, $28.7) RSI Indicator left the oversold zone on March 20, 2024

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that management will participate in the following...

Surmodics to Participate in Upcoming Investor Conferences in March and April

Surmodics (SRDX, $32.79) Moving Average Convergence Divergence (MACD) Histogram turned positive on February 23, 2024

Surmodics (SRDX, $32.95) Moving Average Convergence Divergence (MACD) Histogram turned positive on February 14, 2024

Surmodics (SRDX, $30.75) RSI Indicator left the oversold zone on February 05, 2024

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Surmodics earnings selloff a buying opportunity, says Barrington

Surmodics ( NASDAQ:SRDX ) First Quarter 2024 Results Key Financial Results Revenue: US$30.6m (up 23% from 1Q 2023). Net...

Surmodics First Quarter 2024 Earnings: Beats Expectations

This is a Bearish indicator signaling SRDX's price could decline from here. Traders may explore shorting the stock or put options...

Surmodics (SRDX, $32.38) Moving Average Convergence Divergence (MACD) Histogram turned negative on February 1, 2024

Surmodics, Inc. engages in the provision of surface modification technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays. It also develops and commercializes medical devices that are designed to address unmet clinical needs and engineered to the most demanding requirements. The firm operates through the following segments: Medical Device, In Vitro Diagnostics, and Corporate. The Medical Device segment designs, develops, and manufactures vascular interventional medical devices, surface modification coating technologies, as well as drug-delivery coating technologies. The In Vitro Diagnostics segment is composed of component products and technologies for diagnostic test kits and biomedical research applications. The company was founded in June 1979 and is headquartered in Eden Prairie, MN.

Volume (M)	54,909.00
52-Wk High	$39.41
52-Wk Low	$16.79

SRDX Surmodics, Inc.

About

Feed

News

Sentiment

Earnings

Fundamentals